Product Pipeline

Improved Fibrinogen

Improved liquid formulation.

CSL787 Nebulised Ig

Research program on Nebulised Ig for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease

P. gingivalis POD* OH-CRC

Vaccine to prevent and treat the severe gum disease Periodontitis, caused by the bacterium Porphyromonas gingivalis.
* Partnered Project

Discovery Projects

Discovery projects aiming to grow CSL’s R&D pipeline in our five Therapeutic Areas.

HIZENTRA® DM

HIZENTRA™, 20% subcutaneous immunoglobulin, for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).

HIZENTRA® SSc

HIZENTRA™, 20% subcutaneous immunoglobulin, for the treatment of Systemic Sclerosis (SSc).

PRIVIGEN® SSc

PRIVIGEN®, 10% intravenous immunoglobulin, for the treatment of Systemic Sclerosis (SSc).

HAEGARDA® Japan

Self-administered, subcutaneous C1-esterase inhibitor (human) for routine prophylaxis to prevent HAE attacks.

CSL730* rFc Multimer

Novel recombinant human Fc multimer for treatment of patients with immune complex-mediated autoimmune diseases. Developed in collaboration with Momenta Pharmaceuticals.
* Partnered Project

CSL312 Anti-FXIIa in HAE

A humanised anti-factor XIIa monoclonal antibody in development for use in multiple indications including as a subcutaneous therapy for HAE with the potential for administration once every two to three weeks.

CSL334 IL-13R* ASLAN

Monoclonal antibody targeting IL-13Rα1 for the treatment of atopic dermatitis. Licensed to ASLAN Pharmaceuticals.
* Partnered Project

CSL324 Anti-G-CSFR

Recombinant Monoclonal Antibody against the cytokine granulocyte colony stimulating factor receptor for the potential development of a new class of drugs that targets arthritis and other inflammatory diseases.

Mavrilimumab Anti-GM-CSFR*

Recombinant monoclonal antibody against the granulocyte macrophage colony-stimulating factor receptor as a potential treatment for inflammatory diseases.
*Partnered Project

CSL889 Hemopexin in SCD

Research program on plasma-derived Hemopexin for the potential treatment of Sickle Cell Disease.

CSL200 γ-Globin Gene Therapy in SCD

γ-Globin Gene Therapy for Severe Sickle Cell Disease (SCD).

CSL630 pdFVIII Ruide

Plasma-derived Human Factor VIII manufactured in China through the acquisition of Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide).

CSL312 Anti-FXIIa in Thrombosis

A humanized, anti-factor XIIa monoclonal antibody in development for the prevention of contact-activated thrombosis without bleeding risk.

CSL311 Anti-Beta Common

Fully human monoclonal antibody inhibiting GM-CSF, IL-3 and IL-5 signalling by neutralising the ß-common receptor for the potential treatment of complex inflammatory diseases.

CSL346 Anti-VEGF-B

A humanised mAb that antagonises VEGF-B and is administered via subcutaneous injection either as a standalone therapy or in combination with other agents for the potential treatment of diabetic nephropathy, or other conditions associated with aberrant lipid metabolism.

CSL112 Apo-A1

Novel apolipoprotein A-I infusion therapy developed to reduce the high incidence of early recurrent cardiovascular events that occur in the weeks to months following a heart attack.

CSL964 GvHD Preventation

Prevention of acute Graft versus Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic cell transplant (HCT).

CSL964 GvHD Treatment

Treatment of steroid refractory, acute Graft versus Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic cell transplant (HCT).

CSL842 C1-INH AMR

C1-esterase inhibitor (C1-INH) for the treatment of refractory antibody mediated rejection (rAMR) in adult renal transplant recipients.

Clazakizumab Anti IL-6 Vitaeris*

Humanized recombinant monoclonal antibody that binds to and inhibits Interleukin-6 (IL-6) as a therapeutic option for solid organ transplant rejection. Development in collaboration with Vitaeris Inc.
* Partnered Project

HIZENTRA® CIDP US, Japan, EU, AUS

The first 20% high concentration low volume subcutaneous immunoglobulin for convenient self administration. Approval for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

PRIVIGEN® PID Japan

PRIVIGEN®, 10% intravenous immunoglobulin, for the treatment of primary immune deficiency (PID) indications in Japan.

PRIVIGEN® CIDP US, Japan

PRIVIGEN®, 10% intravenous immunoglobulin, approved for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.

CSL830 C1-INH Subcut, EU

Self-administered subcutaneous C1-esterase inhibitor (human), for routine prophylaxis to prevent HAE attacks in adolescent and adult patients.

HAEGARDA® US

Self-administered subcutaneous C1-esterase inhibitor (human), for routine prophylaxis to prevent HAE attacks in adolescent and adult patients.

KCENTRA® Japan

Lyophilized formulation of plasma-derived concentrate of coagulation factors II, VII, IX, X, Protein C and Protein S used as intravenous administration in patients with acquired deficiency of coagulation factors due to vitamin K antagonist (e.g. Warfarin) therapy.

IDELVION®

Novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B. Delivers high-level protection with up to 14-day dosing in appropriate patients.

AFSTYLA®

Novel long-lasting recombinant factor VIII single-chain therapy for adults and children with haemophilia A.

ZEMAIRA®/RESPREEZA® AAT

Alpha1-Proteinase Inhibitor (Human) for treatment of Alpha- 1 Antitrypsin (AAT) Deficiency.